Skip to main content

Krishnamohan Neha's Form 4 filing

Arcutis Biotherapeutics, Inc. (ARQT) · filed Nov 17, 2025

Accession no.
0001866171-25-000007
Filed
Nov 17, 2025
Trade date
Nov 13, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $939.5K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Krishnamohan NehaCIK 0001866171Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 13, 2025Common StockMOption exerciseAcquired+27,052$8.63+$233,458.7650,407Direct
Nov 13, 2025Common StockMOption exerciseAcquired+12,220$7.51+$91,772.262,627Direct
Nov 13, 2025Common StockSSaleDisposed−39,272$23.19F2−$910,717.6823,355Direct
Nov 13, 2025Common StockSSaleDisposed−1,232$23.37−$28,791.8422,123Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 13, 2025Common StockMOption exerciseDisposed−27,052$0.00$00Direct
Nov 13, 2025Common StockMOption exerciseDisposed−12,220$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $22.86 to $23.60, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)